How Positive Trial Results At Amgen (AMGN) Have Changed Its Investment Story
How Positive Trial Results At Amgen (AMGN) Have Changed Its Investment Story Simply Wall St
Covered in this story
Analyst targets on Amgen
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 47 stories mentioning Amgen, the earliest published 30 Mar 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.